

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

219019Orig1s000

Trade Name: Qfitlia injection

Generic or Proper Name: fitusiran

Sponsor: Genzyme Corporation

Approval Date: March 28, 2025

Indication: For routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors

CENTER FOR DRUG EVALUATION AND RESEARCH

219019Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Officer/Employee List	X
Integrated Review(s)	X
Product Quality Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	X
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

219019Orig1s000

APPROVAL LETTER

NDA 219019

NDA APPROVAL

Genzyme Corporation
Attention: Amanda Meisel, PharmD, RPh
Regulatory Strategist, GRA
55 Corporate Drive
Bridgewater, NJ 08807

Dear Dr. Meisel:

Please refer to your new drug application (NDA) dated and received March 28, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Qfitlia (fitusiran) injection.

This NDA provides for the use of Qfitlia (fitusiran) injection for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 219019.**” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Qfitlia (fitusiran) injection shall be as follows:

- A shelf life of 36 months is granted for the 20 mg drug product in a 0.2 mL single-dose vial (100 mg/mL) when stored either at 2°C to 8°C (36°F to 46°F) or at 15°C to 30°C (59°F to 86°F).
- A shelf life of 24 months is granted for the 50 mg drug product in a 0.5 mL single-dose prefilled pen (100 mg/mL) when stored at 2°C to 8°C. The 50 mg drug product may be stored at 15°C to 30°C (59°F to 86°F) for a single period of up to 3 months at the end of storage within the shelf life of 24 months.

The expiration date for the packaged 50 mg drug product, Qfitlia in a single-dose prefilled pen, shall be dependent on the shortest expiration date of any component.

ADVISORY COMMITTEE

Your application for Qfitlia was not referred to an FDA advisory committee because the application did not raise significant public health questions on the role of the drug in the diagnosis, cure, mitigation, treatment, or prevention of a disease.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

Your single-dose prefilled pen product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.⁶

REQUESTED ENHANCED PHARMACOVIGILANCE (EPV)

We request that for Qfitlia you submit all serious and non-serious domestic and foreign cases of thrombotic events, hepatotoxicity, and acute gallbladder disease including cholelithiasis and cholecystitis as 15-day “Alert reports” (described under 21 CFR 314.80(c)(1)) through the 5th year following initial U.S. approval date.

We request that you provide separate narrative summary analyses of thrombotic events, hepatotoxicity, and acute gallbladder disease including cholelithiasis and cholecystitis reported with Qfitlia as part of your required periodic safety reports (e.g., periodic adverse drug experience report (PADER) required under 21 CFR 314.80(c)(2)), quarterly during the first 3 years post-approval and annually thereafter, through the 5th year following initial U.S. approval date.

Your analyses should include interval and cumulative data relative to the date of approval of Qfitlia. Your analyses should provide an assessment of causality, with documentation of indication (including all labeled and off-label use), temporal

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

⁶ <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>

association, dose and duration of therapy, associated signs and symptoms, confounders, underlying risk factors, treatment given for the event, outcome, and dechallenge/rechallenge. For reports of cholelithiasis, your analysis should provide additional information on the type and composition of stone for each reported case and cumulatively, if available.

POST APPROVAL FEEDBACK MEETING

New molecular entities qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website⁷.

⁷ <https://www.uspnf.com/>

If you have any questions, call Bijal Patel, Regulatory Project Manager, at (240) 402-4829 or at bijal.patel1@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Hylton V. Joffe, MD, MMSc
Director
Office of Cardiology, Hematology,
Endocrinology, and Nephrology
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

HYLTON V JOFFE
03/28/2025 04:53:11 PM